Halaby, RimPopma, Christopher J.Cohen, AnderChi, GeraldZacarkim, Marcelo RodriguesRomero, GonzaloGoldhaber, SamuelHull, RussellHernandez, AdrianMentz, RobertHarrington, RobertLip, GregoryPeacock, FrankWelker, JamesMartin-Loeches, IgnacioDaaboul, YazanKorjian, SergeGibson, Charles2015-02-022014Halaby, R., C. J. Popma, A. Cohen, G. Chi, M. R. Zacarkim, G. Romero, S. Z. Goldhaber, et al. 2014. “d-Dimer elevation and adverse outcomes.” Journal of Thrombosis and Thrombolysis 39 (1): 55-59. doi:10.1007/s11239-014-1101-6. http://dx.doi.org/10.1007/s11239-014-1101-6.0929-5305http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890728d-Dimer is a biomarker of fibrin formation and degradation. While a d-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VTE), the prognostic association of an elevated d-dimer with adverse outcomes has received far less emphasis. An elevated d-dimer is independently associated with an increased risk for incident VTE, recurrent VTE, and mortality. An elevated d-dimer is an independent correlate of increased mortality and subsequent VTE across a broad variety of disease states. Therefore, medically ill subjects in whom the d-dimer is elevated constitute a high risk subgroup in which the prospective evaluation of the efficacy and safety of antithrombotic therapy is warranted.en-USDeep vein thrombosisMortalityPrognosisPulmonary embolismJournal Article2015-02-0210.1007/s11239-014-1101-6